Johnson & Johnson filings document the regulatory record for a New Jersey healthcare company with Innovative Medicine and MedTech operations. Recent 8-K reports cover sales and earnings releases, dividend actions, annual meeting voting results and other material corporate events.
The company’s proxy materials describe board elections, executive compensation votes and shareholder governance matters. Its exchange-registered securities include JNJ common stock and multiple NYSE-listed notes with maturities extending across the company’s long-term debt profile.
HEWSON MARILLYN A reported acquisition or exercise transactions in this Form 4 filing.
Johnson & Johnson director Marillyn A. Hewson reported routine compensation-related awards of Deferred Share Units (DSUs), not open-market stock trades. On March 10, 2026, she received 206.4920 DSUs valued at $242.1400 each, bringing her holdings to 14512.9400 DSUs.
The filing also reflects a prior DSU award of 75.2560 units on March 4, 2025 at $166.1000 per unit. These DSUs represent deferred cash retainers under the company’s Deferred Fee Plan for Directors, are settled in cash when her board service ends, and track the fair market value of one share of common stock plus dividend equivalents.
Pinto Daniel E reported acquisition or exercise transactions in this Form 4 filing.
Johnson & Johnson director Daniel E. Pinto received a grant of 129.058 Deferred Share Units, credited at a reference price of $242.14 per unit, in connection with deferring his cash director retainer. These units track the value of one common share each and are to be settled in cash when his board service ends, bringing his total deferred units to 462.069 including dividend-equivalent accruals.
Johnson & Johnson director Eugene A. Woods received a grant of deferred share units as part of his board compensation. On this date, he acquired 154.869 Deferred Share Units (DSUs), each valued at 242.1400 per unit, bringing his total DSU balance to 5,240.094 units.
The DSUs represent deferred cash retainer fees under the company’s Amended and Restated Deferred Fee Plan for Directors and are to be settled in cash when his directorship ends. Each DSU tracks the fair market value of one share of Johnson & Johnson common stock, and the balance includes dividend equivalent rights credited on outstanding DSUs.
Johnson & Johnson is asking shareholders at its April 23, 2026 virtual annual meeting to elect 12 directors, approve executive pay on an advisory basis, ratify PricewaterhouseCoopers as 2026 auditor, and vote on a shareholder proposal for an independent board chair, which the Board recommends against.
The Board remains mostly independent, with a combined Chairman/CEO structure balanced by a powerful Lead Independent Director role and fully independent key committees. The proxy details board refreshment, committee responsibilities, Enterprise Risk Management, cybersecurity and sustainability oversight, and a pay-for-performance program heavily weighted to long-term equity incentives.
Directors and executives show meaningful stock ownership and strong Say on Pay support in 2025, while large institutional holders such as Vanguard, BlackRock and State Street are disclosed. The Board highlights active shareholder engagement and oversight of a potential separation of the Orthopaedics business through a Special Committee.
Johnson & Johnson executive Robert J. Decker, VP Corporate Controller, exercised employee stock options for 4,075 shares of common stock on February 27, 2026 and immediately received those shares at an exercise price of $115.67 per share. He then sold 4,075 shares of common stock the same day in an open-market transaction at an average price of $247.87 per share, leaving him with 23,682 shares of common stock held directly.
In addition to his direct holdings, Decker is reported as having 134 shares of common stock held indirectly through an ESOP under the Johnson & Johnson Savings Plan and 646 shares held indirectly through a 401(k) plan, both as of the plans’ most recent reporting date of February 28, 2026.
Johnson & Johnson executive Robert J. Decker, VP Corporate Controller, exercised employee stock options for 4,075 shares of common stock on February 27, 2026 and immediately received those shares at an exercise price of $115.67 per share. He then sold 4,075 shares of common stock the same day in an open-market transaction at an average price of $247.87 per share, leaving him with 23,682 shares of common stock held directly.
In addition to his direct holdings, Decker is reported as having 134 shares of common stock held indirectly through an ESOP under the Johnson & Johnson Savings Plan and 646 shares held indirectly through a 401(k) plan, both as of the plans’ most recent reporting date of February 28, 2026.
Johnson & Johnson EVP Timothy Schmid reported an open-market sale of 1,322 shares of common stock at $245.66 per share on February 20, 2026. After this transaction, he directly held 25,447 shares of Johnson & Johnson.
He also reported indirect holdings of 46 shares through an ESOP under the Johnson & Johnson Savings Plan and 745 shares through a 401(k), both based on the plan’s most recent reporting date of January 31, 2026.
Johnson & Johnson insider sale reported. The filing shows a sale of 22,623 common shares by Timothy Schmid on 02/18/2026 for $5,527,545.45. The form also lists a restricted stock vesting of 1,322 shares on 02/13/2026. A broker listed is Fidelity Brokerage Services LLC with an entry date of 02/20/2026.
Johnson & Johnson executive James D. Swanson reported a series of equity compensation transactions and related share sales. On February 13–17, 2026, he exercised employee stock options, restricted share units (RSUs), and performance share units (PSUs) into Johnson & Johnson common stock, with prices on certain option exercises around $162.75–$165.89 per share.
Swanson then conducted open-market sales totaling 62,080 shares of common stock at weighted average prices around $242.70–$243.76, while additional shares were withheld to cover tax obligations upon RSU and PSU vesting. Following these transactions, he directly owned 25,698.131 shares of Johnson & Johnson common stock.
Separately, on February 15, 2026, he received new equity awards under the company’s Long-Term Incentive Plan, including 19,449 employee stock options and 1,397 RSUs, which vest in three equal annual installments and convert into common stock on a one-for-one basis upon vesting.
Johnson & Johnson executive James D. Swanson reported a series of equity compensation transactions and related share sales. On February 13–17, 2026, he exercised employee stock options, restricted share units (RSUs), and performance share units (PSUs) into Johnson & Johnson common stock, with prices on certain option exercises around $162.75–$165.89 per share.
Swanson then conducted open-market sales totaling 62,080 shares of common stock at weighted average prices around $242.70–$243.76, while additional shares were withheld to cover tax obligations upon RSU and PSU vesting. Following these transactions, he directly owned 25,698.131 shares of Johnson & Johnson common stock.
Separately, on February 15, 2026, he received new equity awards under the company’s Long-Term Incentive Plan, including 19,449 employee stock options and 1,397 RSUs, which vest in three equal annual installments and convert into common stock on a one-for-one basis upon vesting.